Related Experiment Video
Updated: May 18, 2026
09:21
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Experimental therapy approaches for ischemic stroke]
1Neurologische Klinik und Poliklinik, Universitätsklinik Würzburg, Josef-Schneider-Str. 11, 97080 Würzburg, Deutschland. christoph.kleinschnitz@uni-wuerzburg.de
Der Nervenarzt
|September 28, 2012
Summary
Ischemic stroke is a leading cause of death and disability. New treatments focusing on neuroprotection and immune system modulation are needed due to limitations of current therapies like recombinant tissue plasminogen activator (rtPA).
Area of Science:
- Neurology
- Immunology
- Experimental Therapeutics
Context:
- Ischemic stroke is the primary cause of long-term disability and third leading cause of death in industrialized nations like Germany.
- The aging population exacerbates the incidence and urgency of addressing ischemic stroke.
- Current treatments, including recombinant tissue plasminogen activator (rtPA), have limitations, such as a narrow therapeutic window and bleeding risks, necessitating novel approaches.
Purpose:
- To review emerging experimental therapeutic strategies for ischemic stroke with potential clinical applications.
- To highlight advancements in neuroprotection and immune system-targeted therapies for stroke.
- To address the urgent need for alternative treatments beyond conventional intensive care and rtPA.
Summary:
- This review explores novel experimental therapeutic principles for ischemic stroke, focusing on neuroprotection and immunomodulatory strategies.
- It examines treatments that could overcome the limitations of current therapies, such as the restricted time window and contraindications of rtPA.
- The discussion centers on developing new options to combat the growing challenge of ischemic stroke in aging populations.
Impact:
- Identifies promising experimental therapies that could lead to improved clinical outcomes for ischemic stroke patients.
- Provides a foundation for future research into neuroprotective and immune-based treatments for stroke.
- Offers potential solutions to the unmet medical need for effective ischemic stroke interventions, particularly for patients ineligible for or beyond the therapeutic window of rtPA.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...